Top Qs
Timeline
Chat
Perspective

Nafamostat

Chemical compound From Wikipedia, the free encyclopedia

Nafamostat
Remove ads

Nafamostat mesylate (INN), a synthetic serine protease inhibitor, is a short-acting anticoagulant,[1] and it is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties.[2] Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin.[3] The mechanism of action of nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition.[4][5]

Quick facts Clinical data, AHFS/Drugs.com ...

It inhibits a large number of Lys/Arg specific serine proteinases, and is also a tryptase inhibitor, which is implicated in leaking blood vessels which is symptomatic of dengue hemorrhagic fever and of end-stage dengue shock syndrome.[6] It is available in a generic form already used for the treatment of certain bleeding complications in some countries, there are risks of severe complications such as: agranulocytosis, hyperkalemia, and anaphylaxis which must be weighed in non-emergency care.[7] In some countries, it used as a treatment for pancreatitis and pancreatic cancer.[citation needed]

This drug has been identified as a potential therapy for COVID-19,[8][9] with clinical trials in Japan possibly set to begin in March 2020.[10] With evidence that nafamostat is a potent anti-viral inhibitor in lung cells, a second round of clinical trials in Korea has begun with 10 hospitals participating.[11] Multiple Phase 2/3[12][13][14] and Phase 3[15][16] clinical trials for COVID-19 in different countries are ongoing.

It has also been reported to target tubulin, favorizing its polymerization.[17]


Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads